<p>Drug firm Zydus Cadila has received final approval from the US health regulator to market Midodrine Hydrochloride tablets, used to treat orthostatic hypotension.</p>.<p>The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.</p>.<p>Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Midodrine Hydrochloride tablets in the strengths of 2.5 mg, 5 mg, and 10 mg, Cadila Healthcare said in a regulatory filing.</p>.<p>Zydus Cadila is a part of Cadila Healthcare group.</p>.<p>The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.</p>.<p>The group now has 298 approvals and has so far filed over 390 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 384.60 apiece on BSE, 0.69 per cent higher against their previous close. </p>
<p>Drug firm Zydus Cadila has received final approval from the US health regulator to market Midodrine Hydrochloride tablets, used to treat orthostatic hypotension.</p>.<p>The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.</p>.<p>Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Midodrine Hydrochloride tablets in the strengths of 2.5 mg, 5 mg, and 10 mg, Cadila Healthcare said in a regulatory filing.</p>.<p>Zydus Cadila is a part of Cadila Healthcare group.</p>.<p>The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.</p>.<p>The group now has 298 approvals and has so far filed over 390 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 384.60 apiece on BSE, 0.69 per cent higher against their previous close. </p>